Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares OutstandingShares Outstanding
Ratios

Pliant Therapeutics (PLRX) Leases (2021 - 2026)

Pliant Therapeutics has reported Leases over the past 6 years, most recently at $23.1 million for Q1 2026.

  • Quarterly Leases fell 12.48% to $23.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.1 million through Mar 2026, down 12.48% year-over-year, with the annual reading at $24.0 million for FY2025, 12.03% down from the prior year.
  • Leases was $23.1 million for Q1 2026 at Pliant Therapeutics, down from $24.0 million in the prior quarter.
  • Over five years, Leases peaked at $28.1 million in Q3 2024 and troughed at $1.2 million in Q4 2023.
  • The 5-year median for Leases is $6.1 million (2024), against an average of $14.4 million.
  • Year-over-year, Leases tumbled 77.67% in 2023 and then skyrocketed 2149.63% in 2024.
  • A 5-year view of Leases shows it stood at $5.4 million in 2022, then tumbled by 77.67% to $1.2 million in 2023, then skyrocketed by 2149.63% to $27.2 million in 2024, then dropped by 12.03% to $24.0 million in 2025, then dropped by 3.48% to $23.1 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Leases are $23.1 million (Q1 2026), $24.0 million (Q4 2025), and $24.8 million (Q3 2025).